Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.

Gynecologic oncology 20121001

Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function.

Medical oncology (Northwood, London, England) 20120901

Role of palliative chemotherapy in advanced epithelioid sarcoma.

American journal of clinical oncology 20120801

Small molecule drugs - optimizing DNA damaging agent-based therapeutics.

Current opinion in pharmacology 20120801

Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.

International journal of cancer 20120701

TRAIL and taurolidine enhance the anticancer activity of doxorubicin, trabectedin and mafosfamide in HT1080 human fibrosarcoma cells.

Anticancer research 20120701

A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.

Investigational new drugs 20120601

Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.

Lung cancer (Amsterdam, Netherlands) 20120601

A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.

Cancer chemotherapy and pharmacology 20120601

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology 20120501

Processing of anthracycline-DNA adducts via DNA replication and interstrand crosslink repair pathways.

Biochemical pharmacology 20120501

Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors.

Investigational new drugs 20120401

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.

Investigational new drugs 20120401

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.

Annals of oncology : official journal of the European Society for Medical Oncology 20120301

Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.

Annals of oncology : official journal of the European Society for Medical Oncology 20120301

A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.

European journal of cancer (Oxford, England : 1990) 20120301

PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma.

The Journal of clinical investigation 20120301

Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies.

Cancer chemotherapy and pharmacology 20120201

Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.

Clinical and experimental immunology 20120201

A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.

Gynecologic oncology 20120101

Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma.

Expert opinion on drug metabolism & toxicology 20120101

Administration of 24-h intravenous infusions of trabectedin in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps: an effective and patient-friendly palliative treatment option.

Onkologie 20120101

A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.

PloS one 20120101

Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.

Current pharmaceutical design 20120101

Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcoma.

Onkologie 20120101

Trabectedin in advanced soft tissue sarcoma: case series.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20120101

Activity of trabectidin in desmoplastic small round cell tumor.

Medical oncology (Northwood, London, England) 20111201

Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.

Gynecologic oncology 20111201

Meta-omic characterization of the marine invertebrate microbial consortium that produces the chemotherapeutic natural product ET-743.

ACS chemical biology 20111118

Systemic management strategies for metastatic soft tissue sarcoma.

Drugs 20111112

Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.

Cancer chemotherapy and pharmacology 20111101

Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease.

Cancer chemotherapy and pharmacology 20111101

Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer.

Gynecologic oncology 20110901

XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids.

Chemistry & biology 20110826

ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.

Cancer 20110801

Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimes: a phase II study of the Gynecologic Oncology Group.

Gynecologic oncology 20110801

Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.

Molecular cancer therapeutics 20110801

The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110701

Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: new molecular insight into the mechanism of action.

European journal of pharmacology 20110511

Prolonged clinical response to trabectedin in a heavily pretreated patient with advanced uterine leiomyosarcoma: a case report and literature review.

Gynecologic oncology 20110501

Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.

European journal of cancer (Oxford, England : 1990) 20110501

Introduction. Trabectedin treatment in GYN cancers.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20110501

Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20110501

An increasing role for trabectedin in gynecological cancers: efficacy in uterine sarcomas.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20110501

Safety profile of trabectedin in combination with liposomal pegylated doxorrubicin in relapsed ovarian carcinoma: considerations for optimal management.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20110501

Trabectedin for the treatment of relapsed ovarian cancer.

Health technology assessment (Winchester, England) 20110501

Trabectedin in the treatment of metastatic soft-tissue sarcoma: cost-effectiveness and cost-utility are yet to be proved.

Annals of oncology : official journal of the European Society for Medical Oncology 20110401

Trabectedin and ovarian cancer: statistical trickery.

Prescrire international 20110401

Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group.

Gynecologic oncology 20110301

Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.

Neoplasia (New York, N.Y.) 20110201

Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information.

Annals of oncology : official journal of the European Society for Medical Oncology 20110101

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.

Annals of oncology : official journal of the European Society for Medical Oncology 20110101

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.

Annals of oncology : official journal of the European Society for Medical Oncology 20110101

Trabectedin in ovarian cancer: could we expect more?

Annals of oncology : official journal of the European Society for Medical Oncology 20110101

Mestastatic gastric cancer from malignant fibrous histiocytoma.

Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 20110101

Therapy-related acute myeloid leukemia following treatment with trabectedin for Ewing's sarcoma.

Acta haematologica 20110101

Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity.

Tumori 20110101

Problems in dealing with very rare adverse effects of new anticancer drugs: the example of trabectedin.

Tumori 20110101

[Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].

Revue medicale de Liege 20110101

[Trabectedin registry].

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20110101

Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20101201

Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research 20101015

Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma.

Anti-cancer drugs 20100901

Recent synthetic approaches to 6,15-iminoisoquino[3,2-b]3-benzazocine compounds.

Chemistry (Weinheim an der Bergstrasse, Germany) 20100823

Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients.

Investigational new drugs 20100801

A review of trabectedin (ET-743): a unique mechanism of action.

Molecular cancer therapeutics 20100801

Functional mapping of receptor tyrosine kinases in myxoid liposarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20100715

Trabectedin therapy for sarcomas.

Current opinion in oncology 20100701

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100701

Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100701

[Current impact of natural products in the discovery of anticancer drugs].

Annales pharmaceutiques francaises 20100701

Characterization and analysis of human chordoma cell lines.

Spine 20100601

[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].

Bulletin du cancer 20100601

Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.

Pharmacogenomics 20100601

Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.

Expert review of anticancer therapy 20100601

Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research 20100501

Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.

Health technology assessment (Winchester, England) 20100501

Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.

Investigational new drugs 20100401

[A rare tumour with a distinctive histological appearance].

Annales de pathologie 20100401

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

Cancer research 20100315

Use of chemotherapy for patients with bone and soft-tissue sarcomas.

Cleveland Clinic journal of medicine 20100301

Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.

Drugs 20100212

Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution.

Anti-cancer drugs 20100101

Can hepatocellular carcinoma be treated by Yondelis through targeting both tumor cells and tumor-associated macrophages?

Hepato-gastroenterology 20100101

Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.

Marine drugs 20100101

Treatment with trabectedin: should be indicated to all soft tissue sarcoma histotypes?

Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20100101

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology 20091101

Trabectedin: an anticancer drug from the sea.

Expert opinion on pharmacotherapy 20091101

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090901

[Recommendations for diagnostic and therapeutic management of soft tissue sarcoma].

Bulletin du cancer 20090901

Trabectedin.

British journal of clinical pharmacology 20090901

The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin.

Marine drugs 20090901

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.

European journal of cancer (Oxford, England : 1990) 20090801

Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.

Annals of oncology : official journal of the European Society for Medical Oncology 20090801

Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.

Gynecologic oncology 20090801

Trabectedin.

The oncologist 20090801

Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects.

Prescrire international 20090801

Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines.

Biochemical pharmacology 20090715

Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin.

Molecular cancer therapeutics 20090701

Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition.

Molecular cancer therapeutics 20090701

Trabectedin for the management of soft-tissue sarcoma.

Expert review of anticancer therapy 20090601

Marine natural products.

Clinical advances in hematology & oncology : H&O 20090601

Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma.

Drugs of today (Barcelona, Spain : 1998) 20090601

Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research 20090515

In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping.

Biochemical pharmacology 20090515

Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines.

Cancer chemotherapy and pharmacology 20090501

Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.

European journal of cancer (Oxford, England : 1990) 20090501

Ready for a comeback of natural products in oncology.

Biochemical pharmacology 20090501

Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.

Natural product reports 20090301

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.

Molecular cancer therapeutics 20090201

Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20090201

Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).

Current clinical pharmacology 20090101

Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.

Current medicinal chemistry 20090101

ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines.

PloS one 20090101

Synthetic studies on Et-743. Assembly of the pentacyclic core and a formal total synthesis.

The Journal of organic chemistry 20081219

Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.

Cancer chemotherapy and pharmacology 20081201

Structure elucidation and 1H/13C NMR spectral assignments of four trabectedin related compounds.

Magnetic resonance in chemistry : MRC 20081201

Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.

Clinical cancer research : an official journal of the American Association for Cancer Research 20081015

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20081015

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.

Annals of oncology : official journal of the European Society for Medical Oncology 20081001

In vitro radiosensitisation by trabectedin in human cancer cell lines.

European journal of cancer (Oxford, England : 1990) 20080801

Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment.

Cancer chemotherapy and pharmacology 20080601

Chemotherapeutic management of soft tissue sarcoma.

The Surgical clinics of North America 20080601

Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma.

Expert opinion on pharmacotherapy 20080601

Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin.

Molecular cancer therapeutics 20080501

[Advance of several types of important marine antitumor drugs].

Yao xue xue bao = Acta pharmaceutica Sinica 20080501

Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity.

Toxicology and applied pharmacology 20080401

Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.

Seminars in oncology 20080401

Role of homologous recombination in trabectedin-induced DNA damage.

European journal of cancer (Oxford, England : 1990) 20080301

Synthesis and cytotoxic evaluation of some cribrostatin-ecteinascidin analogues.

Journal of natural products 20080301

Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.

Clinical pharmacology and therapeutics 20080101

Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers.

Molecular cancer therapeutics 20080101

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.

British journal of cancer 20071217

Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.

Cell proliferation 20071201

Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.

Clinical oncology (Royal College of Radiologists (Great Britain)) 20071001

Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.

Future oncology (London, England) 20070801

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.

The Lancet. Oncology 20070701

Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma.

Cancer biology & therapy 20070701

Trabectedin--a targeted chemotherapy?

The Lancet. Oncology 20070701

Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer.

Cancer chemotherapy and pharmacology 20070501

Phase II study of trabectedin in pretreated patients with advanced colorectal cancer.

Clinical colorectal cancer 20070501

Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype.

Investigational new drugs 20070201

Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.

Journal of cellular biochemistry 20070201

New therapeutics for soft-tissue sarcomas in adults.

Oncology (Williston Park, N.Y.) 20070101

Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.

Clinical pharmacokinetics 20070101

Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.

Drugs 20070101

Further insight into the DNA recognition mechanism of trabectedin from the differential affinity of its demethylated analogue ecteinascidin ET729 for the triplet DNA binding site CGA.

Journal of medicinal chemistry 20061116

Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.

Gynecologic oncology 20060901

Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.

Cancer research 20060815

Synthetic studies on Et-743. Asymmetric, stereocontrolled construction of the tetrahydroisoquinoline core via radical cyclization on a glyoxalimine.

Organic letters 20060720

Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates.

Bioorganic & medicinal chemistry letters 20060715

ET-743: a novel agent with activity in soft-tissue sarcomas.

Current opinion in oncology 20060701

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

European journal of cancer (Oxford, England : 1990) 20060701

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.

British journal of cancer 20060605

Scientists are searching the seas for cancer drugs.

Journal of the National Cancer Institute 20060517

ET743: Chemical analysis of the sea squirt Ecteinascidia turbinata ecosystem.

Natural product research 20060510

Stereospecific formal total synthesis of ecteinascidin 743.

Angewandte Chemie (International ed. in English) 20060303

Total synthesis of ecteinascidin 743.

Journal of the American Chemical Society 20060111

In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug.

Investigational new drugs 20060101

[News of the year 2005 in sarcomas].

Bulletin du cancer 20060101

Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.

Drugs in R&D 20060101

Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.

Reviews on recent clinical trials 20060101

DNA structural similarity in the 2:1 complexes of the antitumor drugs trabectedin (Yondelis) and chromomycin A3 with an oligonucleotide sequence containing two adjacent TGG binding sites on opposing strands.

Molecular pharmacology 20051201

The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71.

International journal of oncology 20051201

Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters.

Molecular pharmacology 20051101

DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin.

Chemistry & biology 20051101

New agents and new formulations for the treatment of ovarian cancer.

Clinical advances in hematology & oncology : H&O 20051101

Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.

Investigational new drugs 20051001

In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction.

Anti-cancer drugs 20051001

Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.

Anti-cancer drugs 20050901

Ecteinascidin-743 (ET-743): early test or effective treatment in soft tissue sarcomas?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820

Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways.

Biochemical pharmacology 20050701

RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma.

European journal of cancer (Oxford, England : 1990) 20050701

Synthetic studies toward ecteinascidin 743.

The Journal of organic chemistry 20050527

Hepatotoxicity and metabolism of trabectedin: a literature review.

Pharmacological research 20050501

Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.

Molecular cancer therapeutics 20050501

Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.

Cancer research 20050401

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050320

Marine natural products as anticancer drugs.

Molecular cancer therapeutics 20050201

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050120

A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study.

Clinical cancer research : an official journal of the American Association for Cancer Research 20050115

Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743.

European journal of cancer (Oxford, England : 1990) 20050101

ET-743: a novel agent with activity in soft tissue sarcomas.

The oncologist 20050101

SV40 DNA replication inhibition by the monofunctional DNA alkylator Et743.

Biochemistry 20041109

New drugs from the sea.

Journal of chemotherapy (Florence, Italy) 20041101

Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma.

International journal of cancer 20041010

[Progress in the studies on antitumor natural product ecteinascidin-743].

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20040801

A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours.

European journal of cancer (Oxford, England : 1990) 20040601

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040415

Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro.

Cancer chemotherapy and pharmacology 20040401

Progress in the clinical development of new marine-derived anticancer compounds.

Anti-cancer drugs 20040401

Simple and sensitive liquid chromatographic quantitative analysis of the novel marine anticancer drug Yondelis (ET-743, trabectedin) in human plasma using column switching and tandem mass spectrometric detection.

Journal of mass spectrometry : JMS 20040401

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040301

Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin), an example of potential problems for extrapolation of active drug concentrations from in vitro studies.

Cancer chemotherapy and pharmacology 20040101

The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.

Oncology research 20040101

Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations.

Biochemical pharmacology 20031215

In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects.

British journal of cancer 20031215

New therapeutic strategies for soft tissue sarcomas.

Current treatment options in oncology 20031201

Progress in the development and acquisition of anticancer agents from marine sources.

Annals of oncology : official journal of the European Society for Medical Oncology 20031101

Preclinical and clinical results with the natural marine product ET-743.

Expert opinion on investigational drugs 20031101

In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells.

Experimental hematology 20031101

Transcriptional inhibition of type I collagen gene expression in scleroderma fibroblasts by the antineoplastic drug ecteinascidin 743.

The Journal of biological chemistry 20031010

Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.

Cancer research 20030915

Rationale for drug combinations.

European journal of cancer (Oxford, England : 1990) 20030901

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

European journal of cancer (Oxford, England : 1990) 20030901

The combination of yondelis and cisplatin is synergistic against human tumor xenografts.

European journal of cancer (Oxford, England : 1990) 20030901

Orphan anticancer drug rejected.

The Lancet. Oncology 20030901

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.

Cancer 20030815

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.

Cancer chemotherapy and pharmacology 20030801

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.

Anti-cancer drugs 20030801

Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.

Clinical cancer research : an official journal of the American Association for Cancer Research 20030701

Aquaculture of three phyla of marine invertebrates to yield bioactive metabolites: process developments and economics.

Biomolecular engineering 20030701

Synthetic studies on ecteinascidin-743: constructing a versatile pentacyclic intermediate for the synthesis of ecteinascidins and saframycins.

Organic letters 20030612

[Development of marine-derived anti-cancer compounds].

Gan to kagaku ryoho. Cancer & chemotherapy 20030501

The potent anticancer compound ecteinascidin-743 (ET-743) as its 2-propanol disolvate.

Acta crystallographica. Section C, Crystal structure communications 20030401

Telomere dysfunction increases cisplatin and ecteinascidin-743 sensitivity of melanoma cells.

Molecular pharmacology 20030301

Pregnane X receptor-dependent and -independent effects of 2-acetylaminofluorene on cytochrome P450 3A23 expression and liver cell proliferation.

Biochemical and biophysical research communications 20030110

Trabectedin: ET 743, ecteinascidin 743, Yondelis.

Drugs in R&D 20030101

[Perspectives on the oncologist pharmacopoeia].

Bulletin du cancer 20030101

Ecteinascidin-743.

Clinical journal of oncology nursing 20030101

Use of CFU-GM assay for prediction of human maximum tolerated dose of a new antitumoral drug: Yondelis (ET-743).

Toxicology in vitro : an international journal published in association with BIBRA 20030101

Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.

Expert opinion on investigational drugs 20021201

Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo.

Cancer research 20021201

Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743.

Molecular cancer therapeutics 20021201

Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis.

The Journal of biological chemistry 20021101

Sea squirt assaults sarcomas.

The Lancet. Oncology 20021101

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.

Cancer chemotherapy and pharmacology 20021001

Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.

Clinical cancer research : an official journal of the American Association for Cancer Research 20020901

Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (ET-743) in the female rat.

Cancer research 20020801

Editorial comment on 'In vitro toxicity of ET-743 and Aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: comparison with the clinical results' by Albella and colleagues.

European journal of cancer (Oxford, England : 1990) 20020701

In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results.

European journal of cancer (Oxford, England : 1990) 20020701

Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.

Anti-cancer drugs 20020701

Ecteinascidin-743 inhibits activated but not constitutive transcription.

Cancer research 20020615

Total synthesis of ecteinascidin 743.

Journal of the American Chemical Society 20020612

Transcriptional response pathways in a yeast strain sensitive to saframycin a and a more potent analog: evidence for a common basis of activity.

Chemistry & biology 20020501

Safety and efficacy of ET-743: the French experience.

Anti-cancer drugs 20020501

A clinical armamentarium of marine-derived anti-cancer compounds.

Anti-cancer drugs 20020501

ET-743: more than an innovative mechanism of action.

Anti-cancer drugs 20020501

ET-743: the US experience in sarcomas of soft tissues.

Anti-cancer drugs 20020501

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.

Anti-cancer drugs 20020401

A 3.(ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions.

Journal of medicinal chemistry 20020214

Studies directed to the total synthesis of ET 743 and analogues thereof: an expeditious route to the ABFGH subunit.

Organic letters 20020110

A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research 20020101

ET-743.

Drugs 20020101

Unique features of the mode of action of ET-743.

The oncologist 20020101

Cytotoxic agents in the era of molecular targets and genomics.

The oncologist 20020101

A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.

The oncologist 20020101

Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650.

Chemistry & biology 20011201

A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.

Cancer chemotherapy and pharmacology 20011201

The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.

Chemistry & biology 20011101

ET-743 (PharmaMar/NCI/Ortho Biotech).

Current opinion in investigational drugs (London, England : 2000) 20011101

Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells.

Clinical cancer research : an official journal of the American Association for Cancer Research 20011001

Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.

Clinical cancer research : an official journal of the American Association for Cancer Research 20010901

[High-dose chemotherapy in soft tissue sarcomas of adults].

Bulletin du cancer 20010901

Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man.

Anti-cancer drugs 20010901

Anticancer squirt.

Nature medicine 20010801

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

Nature medicine 20010801

Differential rates of reversibility of ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favored bonding sites.

Journal of the American Chemical Society 20010711

Transcription of the multidrug resistance gene MDR1: a therapeutic target.

Molecular interventions 20010601

Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.

International journal of cancer 20010515

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux.

Nature medicine 20010501

Okadaic acid induces transcription of junB through a CCAAT box and NF-Y.

Gene 20010404

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010301

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010301

Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research 20010201

Science and serendipity in cancer research.

European journal of cancer (Oxford, England : 1990) 20010101

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

European journal of cancer (Oxford, England : 1990) 20010101

Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.

Clinical cancer research : an official journal of the American Association for Cancer Research 20010101

The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability.

Advances in experimental medicine and biology 20010101